ATE464320T1 - Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) - Google Patents

Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)

Info

Publication number
ATE464320T1
ATE464320T1 AT02758350T AT02758350T ATE464320T1 AT E464320 T1 ATE464320 T1 AT E464320T1 AT 02758350 T AT02758350 T AT 02758350T AT 02758350 T AT02758350 T AT 02758350T AT E464320 T1 ATE464320 T1 AT E464320T1
Authority
AT
Austria
Prior art keywords
ntb
activity
natural killer
killer cells
implied
Prior art date
Application number
AT02758350T
Other languages
English (en)
Inventor
Alessandro Moretta
Cristina Bottino
Roberto Biassoni
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE464320T1 publication Critical patent/ATE464320T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT02758350T 2001-07-19 2002-07-17 Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) ATE464320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401946 2001-07-19
PCT/EP2002/007945 WO2003008449A1 (en) 2001-07-19 2002-07-17 Ntb-a, a surface molecule involved in natural killer cells activity

Publications (1)

Publication Number Publication Date
ATE464320T1 true ATE464320T1 (de) 2010-04-15

Family

ID=8182813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758350T ATE464320T1 (de) 2001-07-19 2002-07-17 Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)

Country Status (8)

Country Link
US (2) US7138243B2 (de)
EP (1) EP1406928B1 (de)
JP (1) JP4326944B2 (de)
AT (1) ATE464320T1 (de)
AU (1) AU2002325333B2 (de)
CA (1) CA2454185A1 (de)
DE (1) DE60235985D1 (de)
WO (1) WO2003008449A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
KR101564713B1 (ko) 2004-12-28 2015-11-06 이나뜨 파르마 Ｎｋｇ2ａ에 대한 단클론 항체
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
ES2902835T3 (es) 2014-01-09 2022-03-30 Hadasit Med Res Service Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
EP3325967B1 (de) 2015-07-24 2019-12-04 Innate Pharma Methoden zur detektion von gewebe-infiltrierenden nk zellen.
US11110171B2 (en) 2017-12-21 2021-09-07 New York University PD-1 related cancer therapy
US11834487B2 (en) 2018-02-12 2023-12-05 Hadasit Medical Research Services & Development Ltd. Modulation of SLAMF6 splice variants for cancer therapy
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN115461451A (zh) * 2020-06-09 2022-12-09 社会福祉法人三星生命公益财团 用于激活和增幅nk细胞的经基因改造的细胞株以及其用途
CN116179488A (zh) * 2023-03-09 2023-05-30 广东唯泰生物科技有限公司 外周血自然杀伤细胞的体外扩增方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
WO2001055336A2 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
US7029677B2 (en) 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2632702A1 (en) * 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
EP1223218A1 (de) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 und CD2001 Moleküle und deren Verwendungen
WO2002077173A2 (en) * 2001-03-22 2002-10-03 Bristol-Myers Squibb Company Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof

Also Published As

Publication number Publication date
AU2002325333B2 (en) 2008-04-03
US20050159332A1 (en) 2005-07-21
WO2003008449A8 (en) 2004-02-26
WO2003008449A1 (en) 2003-01-30
DE60235985D1 (de) 2010-05-27
EP1406928B1 (de) 2010-04-14
JP2005507648A (ja) 2005-03-24
EP1406928A1 (de) 2004-04-14
CA2454185A1 (en) 2003-01-30
US20070065875A1 (en) 2007-03-22
US7138243B2 (en) 2006-11-21
JP4326944B2 (ja) 2009-09-09

Similar Documents

Publication Publication Date Title
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2002031134A3 (en) Novel serine protease genes related to dppiv
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
ATE416258T1 (de) Säure-pilzprotease bei der fermentation von nichtlöslichen stärkesubstraten
DE60144145D1 (de) Subtilisin-variante
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
MX2010003055A (es) Nuevas citocinas aviares y secuencias geneticas que las codifican.
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
WO2004042083A3 (en) Nucleic acid ligands and uses therefor
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
DE60040077D1 (de) Vermehrungsproteine von pflanzen
AU5166200A (en) Human tumor necrosis factor receptor tr10
WO2004029276A3 (en) Nucleic acids encoding a mammalian raptor polypeptide and uses therefor
ATE411338T1 (de) Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties